Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.21EUR
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
€1.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,679
52-wk High
€4.79
52-wk Low
€0.98

Select another date:

Tue, Apr 24 2018

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO

BRIEF-Onxeo Presents Positive AsiDNA Preclinical Study Results

* ANNOUNCES PRESENTATION OF TWO PRECLINICAL STUDY ABSTRACTS HIGHLIGHTING ASIDNA

BRIEF-Onxeo Says To Record Impairment Charge

* ONXEO SA SAYS IT WILL RECORD AN IMPAIRMENT CHARGE OF ABOUT EUR 38 MILLION IN ITS 2017 CONSOLIDATED ACCOUNTS

BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm

* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES

Select another date: